Dec 12, 2019
FIRST PATIENT DOSED IN PHASE I STUDY OF SCB-313 FOR MPE BY CLOVER BIOPHARMACEUTICALS
International clinical-stage biotechnology engaged in generating new and transformative biologic treatments, Clover Biopharmaceuticals publicized today how they had dosed their first patient in a Phase I trial of SCB-313 in Australia for treating cancer patients having malignant pleural effusions. SCB-313 is a fully-human TRAIL-Trimer fusion protein.
Read more...
https://www.industryglobalnews24.com/first-patient-dosed-in-phase-i-study-of-scb313-for-mpe-by-clover-biopharmaceuticals
